arx788
mAbexperimentalADC
Clinical trial activity
11 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
8
Phase 3
1
Phase 4
0
Earliest trial started Mar 1, 2016 (NCT02512237)
Timeline
Indications
Mechanism of action
ERBB2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- Amberstatin269
Oral
No
Parenteral
No
Topical
No
Also known as
- arx788
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06663748 | Phase 2 | Nov 20, 2024 | Henan Medical University |
| NCT06224673 | Phase 2 | Oct 15, 2024 | Ambrx, University of California, San Francisco |
| NCT06578286 | Phase 2 | Sep 30, 2024 | Fudan University |
| NCT05426486 | Phase 2/Phase 3 (Phase 3) | May 23, 2022 | Hengrui Therapeutics, Inc., Shengjing Hospital |
| NCT05041972 | Phase 2 | Oct 31, 2021 | Ambrx |
| NCT05018676 | Phase 2 | Oct 20, 2021 | Fudan University |
| NCT04983121 | Phase 2 | Aug 10, 2021 | China Medical University, Shengjing Hospital |
| NCT05018702 | Phase 2 | Jul 14, 2021 | Fudan University |
| NCT04829604 | Phase 2 | Apr 5, 2021 | Ambrx |
| NCT03255070 | Phase 1 | Mar 12, 2018 | Ambrx |
| NCT02512237 | Phase 1 | Mar 1, 2016 | Ambrx, Zhejiang Medicine Co., Ltd. |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ambrx | For profit | 5 | 3 | 2 | 2016 |
| Fudan University | Academic/Hospital | 3 | 3 | 1 | 2021 |
| Shengjing Hospital | Academic/Hospital | 2 | 2 | 2 | 2021 |
| China Medical University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Henan Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Hengrui Therapeutics, Inc. | For profit | 1 | 0 | 1 | 2022 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Zhejiang Medicine Co., Ltd. | For profit | 1 | 1 | 1 | 2016 |
8 organizations
Page 1 / 1